GlassScriptPhysician profile
Yoichiro Natori
NPI 1225507676
$9,599.41
in general payments reported to CMS, 2019-2025
8 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $189 · 2022: $114 · 2023: $203 · 2024: $8,319 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,264 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,675 · Food and Beverage: $979 · Consulting Fee: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,263.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,674.89 |
| Food and Beverage | $979.18 |
| Consulting Fee | $253.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kamada LTD. | $8,282.48 | 2024-2025 | |
| Lantheus Medical Imaging, INC. | $253.33 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.75 | 2022-2025 | Livtencity |
| Eurofins Viracor, LLC | $198.99 | 2024 | |
| Astellas Pharma US INC | $188.99 | 2020 | |
| Invivyd INC | $164.05 | 2025 | Pemgarda |
| Merck Sharp & Dohme LLC | $159.82 | 2019-2025 | |
| Nobelpharma America, LLC | $105.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yoichiro Natori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.